Kabiven In Plastic Container is a drug owned by Fresenius Kabi Usa Llc. It is protected by 1 US drug patent filed in 2025 out of which none have expired yet. Based on its patents and exclusivities, its generic launch date is estimated to be May 03, 2036. Details of Kabiven In Plastic Container's patents and their expiration are given in the table below.
| Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Status |
|---|---|---|---|
| These drug patents focus on the other aspects of the drug like dosage, mode of administration (oral, tablet, capsules, liquids etc). | |||
| US12390398 | NA |
May, 2036
(10 years from now) | Active |
US patents provide insights into the exclusivity only within the United States, but Kabiven In Plastic Container is protected by patents in multiple countries. Understanding the full scope of patent protection is crucial in strategizing market entry. By looking at the broader patent landscape, you can identify markets with weaker patent protection which could be ideal generic entry points. The following section offers details on Kabiven In Plastic Container's family patents as well as insights into ongoing legal events on those patents.
Kabiven In Plastic Container's Family Patents
Explore Our Curated Drug Screens
Generic Launch
Generic Release Date:
Kabiven In Plastic Container's generic launch date based on the expiry of its last outstanding patent is estimated to be May 03, 2036 (This date is subject to change depending upon the patent filing activities by the drug owner or exclusivity additions to its drug application)
Kabiven In Plastic Container Generics:
There are no approved generic versions for Kabiven In Plastic Container as of now.
Alternative Brands for Kabiven In Plastic Container
There are several other brand drugs using the same active ingredient (Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil) as Kabiven In Plastic Container. Given below is the list of those companies and their brand drugs, to help you identify new opportunities, assess competitors, and plan your market strategies more effectively.
| Drug Owner | Drug Name | |
|---|---|---|
| Fresenius Kabi Usa |
|
About Kabiven In Plastic Container
Kabiven In Plastic Container is a drug owned by Fresenius Kabi Usa Llc. Kabiven In Plastic Container uses Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil as an active ingredient. Kabiven In Plastic Container was launched by Fresenius Kabi Usa in 2014.
Approval Date:
Kabiven In Plastic Container was approved by FDA for market use on 25 August, 2014.
Active Ingredient:
Kabiven In Plastic Container uses Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil as the active ingredient. Check out other Drugs and Companies using Amino Acids; Calcium Chloride; Dextrose; Magnesium Sulfate; Potassium Chloride; Sodium Acetate; Sodium Glycerophosphate; Soybean Oil ingredient
Dosage:
Kabiven In Plastic Container is available in emulsion form for intravenous use. Given below is detailed information on Dosage -
| Strength | Dosage Form | Availability | Application Pathway |
|---|---|---|---|
| 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (1540ML) | EMULSION | Prescription | INTRAVENOUS |
| 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML ;147MG/100ML;3.9GM/100ML (1026ML) | EMULSION | Prescription | INTRAVENOUS |
| 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2566ML) | EMULSION | Prescription | INTRAVENOUS |
| 3.3%;29MG/100ML;9.8GM/100ML;96MG/100ML;174MG/100ML;239MG/100ML;147MG/100ML;3.9GM/100ML (2053ML) | EMULSION | Prescription | INTRAVENOUS |